GlassScriptPhysician profile
Dhurata Guillot
NPI 1841907722
$4,347.30
in general payments reported to CMS, 2019-2025
23 companies · $2,915 in 2025
The $2,915 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $107 · 2024: $1,326 · 2025: $2,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,616 · Travel and Lodging: $549 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,615.63 |
| Travel and Lodging | $548.67 |
| Education | $183.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $726.99 | 2024-2025 | |
| Pacira Pharmaceuticals Incorporated | $623.97 | 2024 | Iovera |
| Janssen Biotech, INC. | $518.97 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $410.47 | 2024-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $272.47 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $256.20 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $207.83 | 2025 | Iqirvo |
| Genzyme Corporation | $202.99 | 2024-2025 | |
| Lilly USA, LLC | $181.29 | 2024-2025 | Omvoh, Zepbound |
| Regeneron Healthcare Solutions, INC. | $181.27 | 2024-2025 | Dupixent |
| Qol Medical, LLC | $151.54 | 2024-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $105.67 | 2024-2025 | Zenpep |
| Pfizer INC. | $83.57 | 2025 | |
| Phathom Pharmaceuticals, INC. | $75.92 | 2025 | Voquezna |
| Bioventus LLC | $66.09 | 2023 | Supartz Fx Sodium Hyaluronate, Gelsyn-3 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $63.22 | 2025 | Pancreaze |
| Madrigal Pharmaceuticals | $61.47 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $40.49 | 2023 | |
| Exact Sciences Corporation | $33.00 | 2025 | The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $29.83 | 2025 | Wegovy |
| Celltrion USA INC. | $18.72 | 2025 | Vegzelma |
| Organon LLC | $17.92 | 2025 | Hadlima |
| Ironwood Pharmaceuticals, INC | $17.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhurata Guillot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.